Pyrotinib provides survival benefit in human epidermal growth factor receptor 2-positive metastatic breast cancer when combined with trastuzumab and docetaxel

1. Pyrotinib combined with trastuzumab and docetaxel prolonged progression-free survival compared to placebo combined with trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The human epidermal growth factor receptor 2 (HER2)-positive subtype of breast cancer involves rapid disease progression and poor prognosis. The combination of pertuzumab, trastuzumab, and docetaxel is the standard of care for the initial treatment of patients with HER2-positive metastatic breast cancer. Pyrotinib is a small molecule that can irreversibly inhibit multiple HER receptor tyrosine kinases and has shown promising antitumour activity. This study presented follow-up results from their phase 3 PHILA study, which examined the efficacy and safety of pyrotinib or placebo in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer. The PHILA trial included female patients aged 18-75 with untreated HER2-positive metastatic breast cancer who were randomly assigned to receive either oral pyrotinib or placebo, both of which were combined with intravenous trastuzumab and docetaxel. The primary outcome of the study was progression-free survival. Out of the 590 patients randomised, 297 received pyrotinib and 293 received placebo. During a median follow-up of 35.7 months in the pyrotinib group and 34.3 months in the placebo group, the pyrotinib group had fewer deaths, 36% lower hazard of death, and showed a sustained improvement in investigator-assessed progression-free survival than the placebo group. With a median follow-up of 45.5 months, the pyrotinib group also showed prolonged progression-free survival compared to the placebo group. Overall, this study found that pyrotinib combined with trastuzumab and docetaxel prolonged progression-free survival compared to placebo combined with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer. 

Click to read the study in the BMJ  

Relevant reading: Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

In-Depth [randomised clinical trial]:

The PHILA trial was a double blind, randomised, placebo-controlled phase 3 trial conducted at 40 study centres in China between May 6th, 2019 and January 17th 2022, and included female patients aged 18-75 with untreated HER2-positive metastatic breast cancer. Patients were randomly assigned 1:1 to receive either oral pyrotinib (400 mg orally once daily) or placebo, both combined with intravenous trastuzumab (8 mg/kg for the first treatment cycle, then 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21-day treatment cycle. The primary outcome was investigator-assessed progression-free survival, defined as the time from randomisation to the first documented radiographic progression or death from any cause, whichever occurred first. Out of the 590 patients randomised, 297 received pyrotinib (mean [IQR] age, 52 [46-58]) and 293 received placebo (mean [IQR] age, 52 [46-57]).  As of April 30th, 2024, the median follow-up was 35.7 months in the pyrotinib group and 34.3 months in the placebo group, with 59 (20%) and 87 (30%) deaths, respectively. Compared to the control group, the pyrotinib group had a 36% lower hazard of death (hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.46 to 0.89; nominal one-sided P = 0.004). Neither group had reached the median overall survival at the end of follow-up. Compared to the placebo group, the pyrotinib group also showed a sustained improvement in progression-free survival (22.1 months [95% CI, 19.3 to 27.8] vs 10.5 months [95% CI, 9.5 to 12.4]; HR, 0.44; 95% CI, 0.36 to 0.53; nominal one-sided P < 0.001). As of May 30th, 2025, with a median follow-up of 45.5 months, the pyrotinib group also showed prolonged progression-free survival (HR, 0.44; 95% CI 0.36 to 0.54; nominal one-sided P < 0.001). The safety profiles observed were consistent with those reported in the previous interim analysis. A total of 91% (n=270) of the patients in the pyrotinib group and 77% (n=227) in the placebo group experienced grade 3 or higher treatment-related adverse events. Overall, this study found that pyrotinib combined with trastuzumab and docetaxel prolonged progression-free survival compared to placebo combined with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer. One major study limitation was that the pertuzumab-trastuzumab combination treatment was not used as a control because it was not approved in China when the study was designed in 2018. Future research should explore biomarkers that predict response and resistance to pyrotinib-based treatments to allow more personalized treatment plans for this population.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.